Home » EMEA: Contrast Agents Associated With Kidney Risk
EMEA: Contrast Agents Associated With Kidney Risk
Manufacturers of contrast agents containing gadolinium
that are used for magnetic resonance scans are being asked to revise the drug labeling to warn of the risk of developing nephrogenic systemic fibrosis
(NSF), the European Medicines Agency (EMEA) says. The recommendation was issued by the agency’s
Committee for Medicinal Products for Human Use after its review of the association between the drugs and NSF, a rare condition characterized by thickening
of connective tissue in the skin, joints, muscles and internal organs in patients with severe kidney problems.
International Pharmaceutical Regulatory Monitor
International Pharmaceutical Regulatory Monitor
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May